Interleukin 6 Blockade as Steroid-sparing Treatment for 2 Patients with Giant Cell Arteritis

REFERENCES

1. 1.↵
   1. Lawrence RC,
   2. Helmick CG,
   3. Arnett FC,
   4. Deyo RA,
   5. Felson DT,
   6. Giannini EH,
   7. et al.

   Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778–99.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Nesher G,
   2. Sonnenblick M,
   3. Friedlander Y

   . Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994;21:1283–6.

   OpenUrlPubMed
3. 3.↵
   1. Pipitone N,
   2. Boiardi L,
   3. Salvarani C

   . Are steroids alone sufficient for the treatment of giant cell arteritis? Best Pract Res Clin Rheumatol 2005;19:277–92.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Jover JA,
   2. Hernandez-Garcia C,
   3. Morado IC,
   4. Banares A,
   5. Fernandez-Gutiérrez B

   . Combined treatment of giant cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:106–14.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Mahr AD,
   2. Jover JA,
   3. Spiera RF,
   4. Hernandez-Garcia C,
   5. Fernandez-Gutierrez B,
   6. La Valley MP,
   7. et al.

   Adjunctive methotrexate for treatment of giant cell arteritis. An individual patient data meta-analysis. Arthritis Rheum 2007;56:2789–97.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Pipitone N,
   2. Salvarani C

   . Improving therapeutic options for patients with giant cell arteritis. Curr Opin Rheumatol 2008;20:17–22.

   OpenUrlPubMed
7. 7.↵
   1. Martínez-Taboada VM,
   2. Rodríguez-Valverde V,
   3. Carreño L,
   4. López-Longo J,
   5. Figueroa M,
   6. Belzunegui J,
   7. et al.

   A double blind placebo controlled trial of etanercept in giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008;67:625–30.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Hoffmann GS,
   2. Cid MC,
   3. Rendt-Zagar K,
   4. Merkel PA,
   5. Weyand CM,
   6. Stone JH,
   7. et al.

   Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. Ann Intern Med 2007;146:621–30.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. García-Martínez A,
   2. Hernández-Rodríguez J,
   3. Espígol-Frigolé G,
   4. Prieto-González S,
   5. Butjosa M,
   6. Segarra M,
   7. et al.

   Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res 2010;62:835–41.

   OpenUrlCrossRef
10. 10.↵
    1. Dasgupta B,
    2. Borg FA,
    3. Hassan N,
    4. Alexander L,
    5. Barraclough K,
    6. Bourke B,
    7. et al.

    BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology 2010;49:1594–7.

    OpenUrlFREE Full Text
11. 11.↵
    1. Hishimoto N,
    2. Nakahara H,
    3. Yoshio-Hoshino N,
    4. Mima T

    . Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008;58:1197–200.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Seitz M,
    2. Reichenbach S,
    3. Bonel HM,
    4. Adler S,
    5. Wermelinger F,
    6. Villiger PM

    . Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011;17:141.

    OpenUrl
13. 13.↵
    1. Bannwarth B,
    2. Richez C

    . Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf 2011;10:123–31.

    OpenUrlCrossRefPubMed